Zomepirac-induced renal failure.

Area of Science:

• Nephrology
• Pharmacology
• Internal Medicine

Background:

• Zomepirac sodium is a newly developed nonsteroidal anti-inflammatory agent (NSAIA) for managing mild to moderate pain.
• The efficacy and safety profile of NSAIAs are crucial for patient care.

Observation:

• Five cases of acute renal failure were observed in patients with previously normal renal function.
• These adverse events occurred following both short-term and long-term exposure to zomepirac sodium.

Findings:

• Patients presented with varying degrees of azotemia, proteinuria, and oliguria, indicative of kidney injury.
• Discontinuation of zomepirac sodium therapy or initiation of prednisone treatment resulted in complete recovery for all affected individuals.

Implications:

• Zomepirac sodium carries a risk of nephrotoxicity, even in patients with no prior renal impairment.
• Clinicians should monitor renal function in patients prescribed zomepirac sodium.
• Alternative pain management strategies may be warranted for patients at risk of renal complications.